Roche, Eli Lilly Alzheimer's Blood Test to Get Expedited FDA Review
By Adria Calatayud
Roche Holding said a blood test for earlier diagnosis of Alzheimer's disease it is developing together with Eli Lilly will get an expedited review by the U.S. Food and Drug Administration.
The Swiss pharmaceutical giant said Thursday that the Elecsys pTau217 test received the so-called breakthrough device designation from the FDA, a program designed to accelerate development and review of medical devices.
Roche said the test relies on a biomarker that has shown the ability to distinguish Alzheimer's disease from other neurodegenerative disorders and strong performance relative to other biomarkers in research settings.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
April 11, 2024 01:33 ET (05:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software